News
GMAB
26.28
+0.61%
0.16
Weekly Report: what happened at GMAB last week (0622-0626)?
Weekly Report · 8h ago
Genmab Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $38 Price Target
Benzinga · 6d ago
Ram Selvaraju Reiterates Buy on Genmab, Keeps EPKINLY-Driven Outlook with Unchanged $38 Price Target
TipRanks · 6d ago
Weekly Report: what happened at GMAB last week (0615-0619)?
Weekly Report · 06/22 09:13
Genmab Updates Articles of Association, Extends Capital-Raising Powers
TipRanks · 06/17 15:58
Genmab Announces Minor Capital Increase Following Employee Warrant Exercise
TipRanks · 06/16 19:59
Genmab issued share capital totals 62,353,252 shares, matching voting rights after warrant exercise
PUBT · 06/16 19:17
Genmab issues 185 shares after employee warrant exercise at DKK 1,334.5 each
PUBT · 06/16 19:12
Genmab Discloses Orbis as New 4.99% Major Shareholder
TipRanks · 06/15 16:27
Genmab Discloses Orbis Investment Management Holds 4.99% Voting Rights Stake Of The Company As Of June 12, 2026
Benzinga · 06/15 16:10
GENMAB - ORBIS INVESTMENT MANAGEMENT HOLDS 4.99% OF GENMAB VOTING RIGHTS AS OF JUNE 12, 2026
Reuters · 06/15 16:04
Orbis Investment Management reports 4.99% stake in Genmab
PUBT · 06/15 16:04
Genmab Updates Articles of Association to Expand Capital-Raising Flexibility
TipRanks · 06/15 15:29
Matt Phipps Reiterates Buy on Genmab as Strong Epkinly Data Offset Missed Overall Survival Endpoint and Support Long-Term Upside
TipRanks · 06/15 14:15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB), Dianthus Therapeutics (DNTH) and Aurora Cannabis (ACB)
TipRanks · 06/15 12:10
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Genmab (GMAB)
TipRanks · 06/15 12:00
Weekly Report: what happened at GMAB last week (0608-0612)?
Weekly Report · 06/15 09:13
Reported Saturday, Genmab's Epcoritamab Monotherapy Achieves 67% ORR And 58% CR Rate While Combination With R-Mini-CHOP Delivers 93% ORR And 86% CR In Elderly Newly Diagnosed DLBCL Patients
Benzinga · 06/15 07:13
Genmab announces new data from studies evaluating epcoritamab
TipRanks · 06/14 21:15
More
Webull provides a variety of real-time GMAB stock news. You can receive the latest news about Genmab through multiple platforms. This information may help you make smarter investment decisions.
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.